Harding Kira, Emblin Kate, Ichim Anca, Adlington Daniel, Daniels Rob, Mokbel Kinan
Department of Health and Care Professions, Faculty of Health and Life Sciences, University of Exeter, Exeter, U.K.
Royal Devon University NHS Foundation Trust, Exeter, U.K.
In Vivo. 2025 Mar-Apr;39(2):1182-1189. doi: 10.21873/invivo.13922.
BACKGROUND/AIM: Chronic kidney disease (CKD) contributes significantly to morbidity, mortality, and healthcare costs. CKD is not only an independent risk factor for cardiovascular disease (CVD) but also a severe complication for patients with CVD, impacting substantially their prognosis and quality of life.
A 79-year-old male with a complex medical history, including asthma, hypertension, myocardial infarction, ischaemic heart disease, and recent atrial fibrillation, presented with new-onset exertional breathlessness and peripheral oedema following cardiac arrest and pacemaker insertion. Investigations, including medication reviews conducted shortly after in an outpatient setting, revealed severe renal impairment with creatinine levels at 250 μmol/l (reference range for adult males: 59-104), representing an initial acute kidney injury (AKI) that did not resolve and resulted in the diagnosis of stage 4 CKD (eGFR 25 ml/min/1.73 m). The patient was treated with furosemide, dapagliflozin, and adjusted doses of ramipril and edoxaban. Following treatment, the patient's symptoms ameliorated and renal function slightly improved (eGFR 27 ml/min/1.73 m).
This case highlights the importance of individualised treatment for patients with CKD alongside complex cardiovascular multi-morbidity. The administration of dapagliflozin and furosemide, together with careful adjustments to ramipril, were instrumental in stabilising the patient's renal function and alleviating symptoms. This case demonstrates how a multifaceted approach, continuous monitoring, and patient education are essential for achieving optimal outcomes in patients with CKD and cardiovascular comorbidities.
背景/目的:慢性肾脏病(CKD)对发病率、死亡率和医疗成本有重大影响。CKD不仅是心血管疾病(CVD)的独立危险因素,也是CVD患者的严重并发症,对其预后和生活质量有重大影响。
一名79岁男性,有复杂的病史,包括哮喘、高血压、心肌梗死、缺血性心脏病和近期房颤,在心脏骤停和植入起搏器后出现新发劳力性呼吸困难和外周水肿。包括在门诊就诊后不久进行的药物审查在内的检查显示,严重肾功能损害,肌酐水平为250μmol/l(成年男性参考范围:59 - 104),代表最初的急性肾损伤(AKI)未得到缓解,导致诊断为4期CKD(估算肾小球滤过率[eGFR]25 ml/min/1.73 m²)。患者接受了呋塞米、达格列净治疗,并调整了雷米普利和依度沙班的剂量。治疗后,患者症状改善,肾功能略有改善(eGFR 27 ml/min/1.73 m²)。
本病例强调了对合并复杂心血管疾病的CKD患者进行个体化治疗的重要性。使用达格列净和呋塞米,以及仔细调整雷米普利,有助于稳定患者的肾功能并缓解症状。本病例表明,多方面的方法、持续监测和患者教育对于CKD合并心血管疾病患者实现最佳治疗效果至关重要。